Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7,938,059
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
10,477,783
-
Shares change
-
+246,762
-
Total reported value, excl. options
-
$67,370,946
-
Value change
-
+$1,560,507
-
Number of buys
-
27
-
Number of sells
-
-15
-
Price
-
$6.43
Significant Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q4 2020
56 filings reported holding XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share as of Q4 2020.
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10,477,783 shares
.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (1,648,485 shares), ORBIMED ADVISORS LLC (1,086,493 shares), BlackRock Inc. (1,033,503 shares), Ikarian Capital, LLC (826,424 shares), BVF INC/IL (792,892 shares), VANGUARD GROUP INC (734,861 shares), AXA S.A. (568,995 shares), RA CAPITAL MANAGEMENT, L.P. (536,962 shares), STATE STREET CORP (409,910 shares), and New Leaf Venture Partners, L.L.C. (335,000 shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.